on the lack of development of new antibiotics among the biopharmas. This is occurring at the same time that multidrug resistant bacteria are occurring widely. Several of these MDR bacteria infect the lungs (Pseudomonas aeruginosa, non-tuberculosis mycobacteria, Staphlococcus aureus and others). With Cipro being a flurorquinolone, which is among the broadest acting antibiotics against Gram negative and Gram positive organisms (the basic classification characteristic between resistant bacteria with a cell wall and those with just a cell membrane) this form of delivery and type of drug has tremendous therapeutic potential. The other therapeutic method that is slowly evolving is the rotation of antibiotics to overcome MDR and emerging resistant strains. If a physician uses seven days of antibiotic #1, switches to 7 days of antibiotic #2 and then follows with seven days of antibiotic #3, the bacteria get caught in a shifting "kill situation" that prevents them from mutating away from. Then repeat the sequence #1, #2 and #3. This therapeutic regimen parallel the success oncologists have had in treating cancer. Using three drugs in rotation at weekly intervals. It is called "multiple modality therapy." NIH is studying this concept carefully at several clinical sites.